Rheumatoid arthritis-associated polymorphisms are not protective against Alzheimer's disease

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Simmons, Christopher R ^a   Zou, Fanggeng ^b   Younkin, Steven G ^b   Estus, Steven ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA SECRETASE 2;

AGE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENDER; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79956016361     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-33     Document Type: Article

References (65)

1. Rheumatoid arthritis and senile dementia of the Alzheimer's type. ML Jenkinson MR Bliss AT Brain DL Scott, Br J Rheumatol 1989 28 86 88 2917245
2. Anti-inflammatory drugs and Alzheimer disease. PL McGeer E McGeer J Rogers J Sibley, Lancet 1990 335 1037 1970088 (Pubitemid 20148621)
3. Alzheimer's disease and rheumatoid arthritis. R Myllykangas-Luosujarvi H Isomaki, Br J Rheumatol 1994 33 501 502 10.1093/rheumatology/33.5.501 8173862
4. Rheumatoid arthritis. DL Scott F Wolfe TW Huizinga, Lancet 2010 376 1094 1108 10.1016/S0140-6736(10)60826-4 20870100
5. Role of genes and environments for explaining Alzheimer disease. M Gatz CA Reynolds L Fratiglioni B Johansson JA Mortimer S Berg A Fiske NL Pedersen, Arch Gen Psychiatry 2006 63 168 174 10.1001/archpsyc.63.2.168 16461860 (Pubitemid 43213878)
6. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. S Weggen JL Eriksen P Das SA Sagi R Wang CU Pietrzik KA Findlay TE Smith MP Murphy T Bulter, et al. Nature 2001 414 212 216 10.1038/35102591 11700559 (Pubitemid 33051236)
7. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. JL Eriksen SA Sagi TE Smith S Weggen P Das DC McLendon VV Ozols KW Jessing KH Zavitz EH Koo TE Golde, J Clin Invest 2003 112 440 449 12897211 (Pubitemid 38063773)
8. Clinical trial of indomethacin in Alzheimer's disease. J Rogers LC Kirby SR Hempelman DL Berry PL McGeer AW Kaszniak J Zalinski M Cofield L Mansukhani P Willson, et al. Neurology 1993 43 1609 1611 8351023 (Pubitemid 23230557)
9. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. JC Breitner BA Gau KA Welsh BL Plassman WM McDonald MJ Helms JC Anthony, Neurology 1994 44 227 232 8309563 (Pubitemid 24070956)
10. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. CA Szekely RC Green JC Breitner T Ostbye AS Beiser MM Corrada HH Dodge M Ganguli CH Kawas LH Kuller, et al. Neurology 2008 70 2291 2298 10.1212/01.wnl.0000313933.17796.f6 18509093
11. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. CA Szekely JC Breitner AL Fitzpatrick TD Rea BM Psaty LH Kuller PP Zandi, Neurology 2008 70 17 24 10.1212/01.wnl.0000284596.95156.48 18003940
12. Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. JC Breitner SJ Haneuse R Walker S Dublin PK Crane SL Gray EB Larson, Neurology 2009 72 1899 1905 10.1212/WNL.0b013e3181a18691 19386997
13. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. JA Sonnen EB Larson RL Walker S Haneuse PK Crane SL Gray JC Breitner TJ Montine, Neurology 2010 75 1203 1210 10.1212/WNL.0b013e3181f52db1 20811000
14. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. RR Ahmed CJ Holler RL Webb F Li TL Beckett MP Murphy, J Neurochem 2010 112 1045 1053 10.1111/j.1471-4159.2009.06528.x 19968762
15. beta-Secretase activity in rat astrocytes: translational block of BACE1 and modulation of BACE2 expression. B Bettegazzi M Mihailovich A Di Cesare A Consonni R Macco I Pelizzoni F Codazzi F Grohovaz D Zacchetti, The European journal of neuroscience 2011 33 236 243 10.1111/j.1460-9568.2010.07482.x 21073551
16. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. LA Farrer LA Cupples JL Haines B Hyman WA Kukull R Mayeux RH Myers MA Pericak-Vance N Risch CM van Duijn, JAMA 1997 278 1349 1356 10.1001/jama.278.16.1349 9343467 (Pubitemid 27449696)
17. A second generation human haplotype map of over 3.1 million SNPs. KA Frazer DG Ballinger DR Cox DA Hinds LL Stuve RA Gibbs JW Belmont A Boudreau P Hardenbol SM Leal, et al. Nature 2007 449 851 861 10.1038/nature06258 17943122 (Pubitemid 47598626)
18. Functional domains of the BACE1 and BACE2 promoters and mechanisms of transcriptional suppression of the BACE2 promoter in normal neuronal cells. DK Lahiri B Maloney YW Ge, J Mol Neurosci 2006 29 65 80 10.1385/JMN:29:1:65 16757811 (Pubitemid 43853044)
19. Characterization of the human beta-secretase 2 (BACE2) 5'-flanking region: identification of a 268-bp region as the basal BACE2 promoter. B Maloney YW Ge NH Greig DK Lahiri, J Mol Neurosci 2006 29 81 99 10.1385/JMN:29:1:81 16757812 (Pubitemid 43853045)
20. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. X Sun Y Wang H Qing MA Christensen Y Liu W Zhou Y Tong C Xiao Y Huang S Zhang, et al. Faseb J 2005 19 739 749 10.1096/fj.04-3426com 15857888 (Pubitemid 40617378)
21. SNPExpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels. MA Sanders RG Verhaak WM Geertsma-Kleinekoort S Abbas S Horsman PJ van der Spek B Lowenberg PJ Valk, BMC Genomics 2008 9 41 10.1186/1471-2164-9-41 18221515
22. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. M Farzan CE Schnitzler N Vasilieva D Leung H Choe, Proc Natl Acad Sci USA 2000 97 9712 9717 10931940 (Pubitemid 30650841)
23. Altered beta-secretase enzyme kinetics and levels of both BACE1 and BACE2 in the Alzheimer's disease brain. JH Stockley R Ravid C O'Neill, FEBS Lett 2006 580 6550 6560 10.1016/j.febslet.2006.10.076 17113083 (Pubitemid 44827012)
24. Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes. CD Sloan L Shen JD West HA Wishart LA Flashman LA Rabin RB Santulli SJ Guerin CH Rhodes GJ Tsongalis, et al. Am J Med Genet B Neuropsychiatr Genet 2010 153B 1060 1069 10.1002/ajmg.b.31078 20468060
25. Inflammation in neurodegenerative diseases. S Amor F Puentes D Baker P van der Valk, Immunology 2010 129 154 169 10.1111/j.1365-2567.2009.03225.x 20561356
26. Microglia in neurodegenerative disease. VH Perry JA Nicoll C Holmes, Nat Rev Neurol 2010 6 193 201 10.1038/nrneurol.2010.17 20234358
27. Relationship between tau pathology and neuroinflammation in Alzheimer's disease. MJ Metcalfe ME Figueiredo-Pereira, Mt Sinai J Med 2010 77 50 58 10.1002/msj.20163 20101714
28. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. L Bertram MB McQueen K Mullin D Blacker RE Tanzi, Nat Genet 2007 39 17 23 10.1038/ng1934 17192785 (Pubitemid 46026496)
29. Apolipoprotein J (clusterin) activates rodent microglia in vivo and in vitro. Z Xie ME Harris-White PA Wals SA Frautschy CE Finch TE Morgan, J Neurochem 2005 93 1038 1046 10.1111/j.1471-4159.2005.03065.x 15857407 (Pubitemid 40695763)
30. Genome-wide analysis of genetic loci associated with Alzheimer disease. S Seshadri AL Fitzpatrick MA Ikram AL DeStefano V Gudnason M Boada JC Bis AV Smith MM Carassquillo JC Lambert, et al. JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622
31. Complement activation in very early Alzheimer disease. H Zanjani CE Finch C Kemper J Atkinson D McKeel JC Morris JL Price, Alzheimer Dis Assoc Disord 2005 19 55 66 10.1097/01.wad.0000165506.60370.94 15942322 (Pubitemid 41073081)
32. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. EG McGeer PL McGeer, J Alzheimers Dis 2010 19 355 361 20061650
33. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. MK McCoy MG Tansey, J Neuroinflammation 2008 5 45 10.1186/1742-2094-5-45 18925972
34. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. G Conductier N Blondeau A Guyon JL Nahon C Rovere, J Neuroimmunol 2010
35. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. J El Khoury M Toft SE Hickman TK Means K Terada C Geula AD Luster, Nat Med 2007 13 432 438 10.1038/nm1555 17351623 (Pubitemid 46559828)
36. Immune cells may fend off Alzheimer disease. M Britschgi T Wyss-Coray, Nat Med 2007 13 408 409 10.1038/nm0407-408 17415372 (Pubitemid 46559817)
37. Tissue-specific genetic control of splicing: implications for the study of complex traits. EL Heinzen D Ge KD Cronin JM Maia KV Shianna WN Gabriel KA Welsh-Bohmer CM Hulette TN Denny DB Goldstein, PLoS Biol 2008 6 1 19222302
38. Inflammation and Alzheimer's disease. H Akiyama S Barger S Barnum B Bradt J Bauer GM Cole NR Cooper P Eikelenboom M Emmerling BL Fiebich, et al. Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586 (Pubitemid 30349107)
39. Anti-inflammatory therapy for Alzheimer's disease. PS Aisen, Neurobiol Aging 2000 21 447 448 discussion 451-443 10.1016/S0197-4580(00)00140-8 10858592 (Pubitemid 30349113)
40. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. PP Zandi JC Anthony KM Hayden K Mehta L Mayer JC Breitner, Neurology 2002 59 880 886 12297571
41. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. PS Aisen KA Schafer M Grundman E Pfeiffer M Sano KL Davis MR Farlow S Jin RG Thomas LJ Thal, JAMA 2003 289 2819 2826 10.1001/jama.289.21.2819 12783912 (Pubitemid 37430117)
42. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. D de Jong R Jansen W Hoefnagels M Jellesma-Eggenkamp M Verbeek G Borm B Kremer, PLoS One 2008 3 1475 10.1371/journal.pone.0001475 18213383
43. A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein beta-secretase. A Solans X Estivill S de La Luna, Cytogenet Cell Genet 2000 89 177 184 10.1159/000015608 10965118
44. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. D Dominguez J Tournoy D Hartmann T Huth K Cryns S Deforce L Serneels IE Camacho E Marjaux K Craessaerts, et al. J Biol Chem 2005 280 30797 30806 10.1074/jbc.M505249200 15987683 (Pubitemid 41291810)
45. VISTA: computational tools for comparative genomics. KA Frazer L Pachter A Poliakov EM Rubin I Dubchak, Nucleic Acids Res 2004 32 273 279 10.1093/nar/gkh458 15215394
46. PROMO: detection of known transcription regulatory elements using species-tailored searches. X Messeguer R Escudero D Farre O Nunez J Martinez MM Alba, Bioinformatics 2002 18 333 334 10.1093/bioinformatics/18.2.333 11847087 (Pubitemid 34183117)
47. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. D Farre R Roset M Huerta JE Adsuara L Rosello MM Alba X Messeguer, Nucleic Acids Res 2003 31 3651 3653 10.1093/nar/gkg605 12824386 (Pubitemid 37442215)
48. Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men. V Giedraitis L Kilander M Degerman-Gunnarsson J Sundelof T Axelsson AC Syvanen L Lannfelt A Glaser, Dementia and geriatric cognitive disorders 2009 27 59 68 10.1159/000191203 19141999
49. Specific BACE1 genotypes provide additional risk for late-onset Alzheimer disease in APOE epsilon 4 carriers. G Gold JL Blouin FR Herrmann A Michon R Mulligan G Duriaux Sail C Bouras P Giannakopoulos SE Antonarakis, American journal of medical genetics Part B, Neuropsychiatric genetics: the official publication of the International Society of Psychiatric Genetics 2003 119B 44 47 (Pubitemid 37064052)
50. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. H Li S Wetten L Li PL St Jean R Upmanyu L Surh D Hosford MR Barnes JD Briley M Borrie, et al. Archives of neurology 2008 65 45 53 10.1001/archneurol.2007.3 17998437
51. Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study. L Myllykangas F Wavrant-De Vrieze T Polvikoski IL Notkola R Sulkava L Niinisto SD Edland S Arepalli O Adighibe D Compton, et al. J Neurol Sci 2005 236 17 24 10.1016/j.jns.2005.04.008 16023140 (Pubitemid 41222289)
52. Association studies using novel polymorphisms in BACE1 and BACE2. P Nowotny JM Kwon S Chakraverty V Nowotny JC Morris AM Goate, Neuroreport 2001 12 1799 1802 10.1097/00001756-200107030-00008 11435901 (Pubitemid 32553686)
53. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. EM Reiman JA Webster AJ Myers J Hardy T Dunckley VL Zismann KD Joshipura JV Pearson D Hu-Lince MJ Huentelman, et al. Neuron 2007 54 713 720 10.1016/j.neuron.2007.05. 022 17553421 (Pubitemid 46843528)
54. Lack of association between the polymorphisms of beta-site APP-cleaving enzyme 2 (BACE2) 5'-flanking region and sporadic Alzheimer's disease. Y Yu J Jia, Brain Res 2009 1257 10 15 19124009
55. A navigator for human genome epidemiology. W Yu M Gwinn M Clyne A Yesupriya MJ Khoury, Nature genetics 2008 40 124 125 10.1038/ng0208-124 18227866
56. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. AD Johnson RE Handsaker SL Pulit MM Nizzari CJ O'Donnell PI de Bakker, Bioinformatics 2008 24 2938 2939 10.1093/bioinformatics/btn564 18974171
57. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. MM Carrasquillo F Zou VS Pankratz SL Wilcox L Ma LP Walker SG Younkin CS Younkin LH Younkin GD Bisceglio, et al. Nat Genet 2009 41 192 198 10.1038/ng.305 19136949
58. Replication of CLU, CR1, and PICALM associations with alzheimer disease. MM Carrasquillo O Belbin TA Hunter L Ma GD Bisceglio F Zou JE Crook VS Pankratz DW Dickson NR Graff-Radford, et al. Arch Neurol 2010 67 961 964 10.1001/archneurol.2010.147 20554627
59. PLINK: a tool set for whole-genome association and population-based linkage analyses. S Purcell B Neale K Todd-Brown L Thomas MA Ferreira D Bender J Maller P Sklar PI de Bakker MJ Daly PC Sham, Am J Hum Genet 2007 81 559 575 10.1086/519795 17701901 (Pubitemid 47330214)
60. Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. F Zou RK Gopalraj J Lok H Zhu IF Ling JF Simpson HM Tucker JF Kelly SG Younkin DW Dickson, et al. Hum Mol Genet 2008 17 929 935 18065781 (Pubitemid 351426027)
61. A common polymorphism decreases low-density lipoprotein receptor exon 12 splicing efficiency and associates with increased cholesterol. H Zhu HM Tucker KE Grear JF Simpson AK Manning LA Cupples S Estus, Hum Mol Genet 2007 16 1765 1772 10.1093/hmg/ddm124 17517690 (Pubitemid 47241835)
62. Expression and regulation of a low-density lipoprotein receptor exon 12 splice variant. IF Ling RK Gopalraj JF Simpson S Estus, J Neurochem 2010
63. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. J Vandesompele K De Preter F Pattyn B Poppe N Van Roy A De Paepe F Speleman, Genome Biol 2002 3 ESEARCH0034 12184808
64. Role of SFRS13A in low-density lipoprotein receptor splicing. IF Ling S Estus, Hum Mutat 2010 31 702 709 10.1002/humu.21244 20232416
65. Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. X Zhang L Ding AJ Sandford, BMC Mol Biol 2005 6 4 10.1186/1471-2199-6-4 15720708